Srs Capital Advisors, Inc. Enlivex Therapeutics Ltd. Transaction History
Srs Capital Advisors, Inc.
- $1.5 Billion
- Q4 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 1,015 shares of ENLV stock, worth $1,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,015
Previous 615
65.04%
Holding current value
$1,065
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ENLV
# of Institutions
27Shares Held
2.75MCall Options Held
20.8KPut Options Held
3K-
Armistice Capital, LLC New York, NY2.21MShares$2.32 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny634KShares$665,5390.0% of portfolio
-
Morgan Stanley New York, NY270KShares$283,1370.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny159KShares$166,9410.0% of portfolio
-
Sigma Investment Counselors Inc28KShares$29,4000.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $19.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...